VEA
KRYS icon

Virtus ETF Advisers’s Krystal Biotech KRYS Stock Holding History

Virtus ETF Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,016
Closed -$316K – 623
2024
Q4 		$316K Buy
2,016
+214
+12% +$38K 0.13% 238
2024
Q3 		$328K Hold
1,802
– – 0.15% 224
2024
Q2 		$331K Buy
1,802
+1,058
+142% +$178K 0.16% 210
2024
Q1 		$132K Sell
744
-52
-7% -$7.22K 0.07% 340
2023
Q4 		$98.8K Buy
796
+30
+4% +$3.33K 0.06% 365
2023
Q3 		$88.9K Sell
766
-74
-9% -$9.03K 0.05% 350
2023
Q2 		$98.6K Sell
840
-466
-36% -$47.6K 0.06% 390
2023
Q1 		$105K Sell
1,306
-498
-28% -$39.1K 0.06% 333
2022
Q4 		$143K Sell
1,804
-267
-13% -$19.8K 0.07% 357
2022
Q3 		$144K Buy
2,071
+16
+0.8% +$1.16K 0.06% 360
2022
Q2 		$135K Sell
2,055
-144
-7% -$8.96K 0.05% 338
2022
Q1 		$146K Sell
2,199
-137
-6% -$8.55K 0.07% 230
2021
Q4 		$163K Sell
2,336
-952
-29% -$55.4K 0.06% 318
2021
Q3 		$172K Sell
3,288
-167
-5% -$9.89K 0.08% 306
2021
Q2 		$235K Sell
3,455
-1,696
-33% -$118K 0.1% 230
2021
Q1 		$397K Buy
5,151
+99
+2% +$7.2K 0.17% 185
2020
Q4 		$303K Sell
5,052
-1,794
-26% -$89.6K 0.13% 206
2020
Q3 		$295K Sell
6,846
-938
-12% -$40.7K 0.15% 229
2020
Q2 		$322K Buy
7,784
+2,268
+41% +$109K 0.15% 292
2020
Q1 		$239K Sell
5,516
-791
-13% -$41.4K 0.1% 259
2019
Q4 		$349K Sell
6,307
-2,976
-32% -$146K 0.06% 284
2019
Q3 		$322K Sell
9,283
-517
-5% -$23.1K 0.06% 193
2019
Q2 		$395K Buy
+9,800
New +$320K 0.08% 192

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Virtus ETF Advisers's KRYS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 2,016 shares — an estimated $316K sold.

Virtus ETF Advisers first reported a position in KRYS in Q2 2019 and held it in 23 quarters. The position peaked at $397K in Q1 2021. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,016 Krystal Biotech shares in Q1 2025, an estimated $316K.
  • Virtus ETF Advisers first reported a position in Krystal Biotech in Q2 2019 and held it in 23 quarters.
  • Virtus ETF Advisers's Krystal Biotech position peaked at $397K in Q1 2021.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.